Daiichi Sankyo Deutschland GmbH

What Daiichi Sankyo Deutschland GmbH does

Daiichi Sankyo Deutschland GmbH is the German operating subsidiary of Japanese pharmaceutical group Daiichi Sankyo Co., Ltd., headquartered in Munich and serving as the company's European headquarters. The entity was established in 2012 and employs 377 people across Munich (corporate/European HQ), Pfaffenhofen (manufacturing and development, with ongoing capacity expansion for cancer therapies), and Martinsried (Translational Research Center Europe). The business is concentrated in two therapeutic areas — oncology and cardiology — with a marketed oncology portfolio built on its proprietary antibody-drug conjugate (ADC) platform: Enhertu (trastuzumab deruxtecan, HER2-targeted, multiple indications), Datroway (datopotamab deruxtecan, TROP2-targeted, metastatic triple-negative breast cancer), and Vanflyta (quizartinib, FLT3-ITD-positive AML). Clinical evidence includes a 53% reduction in disease recurrence with ENHERTU versus T-DM1 in high-risk HER2+ early breast cancer and a 5-month median overall survival improvement with DATROWAY versus chemotherapy in first-line metastatic TNBC.

Revenue is generated through one-time sales of prescription pharmaceutical products via pharmacy and hospital channels in Germany, with regulatory oversight from BfArM and the Paul-Ehrlich-Institut. The company targets oncology and cardiology healthcare professionals through enterprise field sales, medical-scientific engagement, conferences, and a DocCheck-authenticated HCP portal, and increasingly engages patients directly through digital platforms such as the Verstanden.med cancer information portal. As a wholly-owned subsidiary, its strategy is tightly aligned with the parent group's global oncology pipeline and ADC franchise expansion.

Name

Daiichi Sankyo Deutschland GmbH

Legal name

Daiichi Sankyo Deutschland GmbH

Website

https://daiichi-sankyo.de

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

Daiichi Sankyo Deutschland GmbH is the Munich-based German subsidiary of Japanese pharmaceutical group Daiichi Sankyo, commercializing oncology and cardiology prescription drugs in Germany and serving as its European headquarters.

Ownership category

akta.pro rank

Product category

Oncology and Cardiology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Oncology pharmaceutical products
• Antibody-drug conjugates
• Prescription drug manufacturing
• Cardiology medications
• Clinical research services

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of prescription pharmaceutical products including oncology drugs (Enhertu, Datroway, Vanflyta) and cardiovascular medications. Products are distributed through pharmacy channels and hospital procurement with regulatory oversight from BfArM and Paul-Ehrlich-Institut.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Daiichi Sankyo Deutschland GmbH develops, manufactures, and distributes prescription pharmaceutical products for the German and broader European market, with its commercial portfolio focused on oncology (Datroway, Enhertu, Vanflyta) and cardiology. The company's pipeline is anchored by its proprietary Antibody-Drug Conjugate (ADC) technology platform used in targeted cancer therapy. It also operates production and translational research facilities in Germany (Pfaffenhofen and Martinsried).

Product overview

Daiichi Sankyo Deutschland GmbH operates as the German subsidiary of the global Japanese pharmaceutical company Daiichi Sankyo. The company's product portfolio focuses on two core therapeutic areas: Oncology and Cardiology. In Oncology, the marketed products include three main prescription pharmaceuticals: Datroway (an anti-TROP2 antibody-drug conjugate for triple negative breast cancer), Enhertu (a HER2-targeted antibody-drug conjugate with multiple cancer indications including breast, lung, and gastric cancers), and Vanflyta (a FLT3 inhibitor for acute myeloid leukemia). The company maintains an active oncology product pipeline under clinical development. In Cardiology, the company focuses on cardiovascular treatments. All prescription pharmaceutical products require HCP authentication (via DocCheck) for access to detailed product information, consistent with German pharmaceutical regulations.

Differentiator

Problem solved

Functional benefit

Brands

• GI 4.0 (Gebrauchsinformation 4.0): Digital package leaflet platform for accessing medication information via smartphone app or PC
• DSPACE
• Verstanden.med

Products and services

• Enhertu (Trastuzumab deruxtecan)

Quantifiable outcome

• 53% reduction in risk of disease recurrence or death with ENHERTU vs T-DM1 in high-risk HER2+ early breast cancer (DESTINY-Breast05 trial)
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Dr. Veronika RozehnalcoreStrategic or Co-development Partner · 22 January 2026Dr. Veronika Rozehnal appointed as the new head of the Translational Research Center Europe in Martinsried near Munich, succeeding Dr. Jürgen Müller. This represents a strategic leadership appointment for the company's European research operations.
• DocCheck Medical Services GmbHcoreTechnology or IntegrationDocCheck provides HCP authentication and access control services for the restricted areas of the Daiichi Sankyo website, ensuring prescription product information is only accessible to verified healthcare professionals as required by regulatory obligations.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Pfizer Pharma GmbH: Pfizer operates a major oncology franchise including ADC programs (acquired Seagen) and competes with Daiichi Sankyo's ADC platform. Pfizer Pharma GmbH serves the same German oncology HCPs and hospital procurement channels.
• Roche Pharma AG: Roche is the long-standing leader in HER2-targeted oncology with Herceptin, Perjeta, Kadcyla, and Phesgo, directly competing with Daiichi Sankyo's Enhertu across HER2-positive breast cancer indications. Roche Pharma AG operates the German affiliate serving the same oncology HCPs and hospital channels.
• Novartis Pharma GmbH: Novartis is a broad incumbent in oncology and cardiology with established products (Kisqali, Lutathera, Pluvicto, Entresto) and ADC development efforts. Novartis Pharma GmbH competes with Daiichi Sankyo Deutschland across both of its core therapeutic areas and the same German HCP channels.

Direct peers

• Merck Healthcare KGaA: Merck KGaA is a Germany-headquartered oncology competitor with Erbitux and an emerging pipeline including tepotinib, serving the same German oncology HCPs. Its oncology focus and German headquarters make it a directly comparable specialty oncology peer.
• Bayer AG (Pharmaceuticals): Bayer's pharmaceutical division operates a cardiovascular franchise (Xarelto, Eylea) and oncology pipeline (Nubeqa) overlapping Daiichi Sankyo's cardiology heritage and emerging oncology presence. Bayer's German headquarters and similar therapeutic focus make it a directly relevant peer.
• Gilead Sciences GmbH: Gilead's Trodelvy (sacituzumab govitecan) is a TROP2-directed ADC directly competing with Datroway in metastatic triple-negative breast cancer. As an emerging ADC-focused player, Gilead is the most direct head-to-head competitor to Daiichi Sankyo's TROP2 franchise.
• AstraZeneca GmbH: AstraZeneca is Daiichi Sankyo's co-development partner on Enhertu and Datroway, making it both an allied and competing force in HER2 and TROP2 ADCs. AstraZeneca GmbH runs the German commercial organization for these joint products, directly overlapping Daiichi Sankyo Deutschland's oncology franchise and customer base.
• Bristol-Myers Squibb GmbH: BMS is a major oncology player with hematology and solid tumor franchises overlapping Daiichi Sankyo's AML product Vanflyta and broader oncology portfolio. Bristol-Myers Squibb GmbH targets the same oncology specialists in German hospitals and clinics.
• Boehringer Ingelheim Pharma GmbH & Co. KG: Boehringer Ingelheim is a major Germany-based pharma peer with a strong cardiology heritage (anticoagulants, heart failure) and growing oncology presence, directly comparable to Daiichi Sankyo's dual oncology/cardiology focus and operating from a similar German base.
• Amgen GmbH: Amgen operates a biologic oncology franchise (Blincyto, Lumakras, Imdelltra) and ADC-adjacent pipeline, with a German affiliate targeting the same oncology specialists and hospital channels as Daiichi Sankyo Deutschland. Its biotech-style focus makes it a directly comparable specialty oncology peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/daiichi-sankyo-deutschland-gmbh

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiichi Sankyo Deutschland GmbH